DB:2OB

Stock Analysis Report

Executive Summary

Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumour diagnostic agents.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Share Price & News

How has Oncolys BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2OB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.6%

2OB

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

229.9%

2OB

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: 2OB exceeded the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: 2OB exceeded the German Market which returned 10.9% over the past year.


Shareholder returns

2OBIndustryMarket
7 Day0.6%5.5%-0.3%
30 Day0.6%-0.8%2.6%
90 Day-14.2%-4.8%11.8%
1 Year229.9%229.9%-1.6%-1.9%14.4%10.9%
3 Year110.6%110.6%65.5%63.4%24.1%13.2%
5 Year180.1%180.1%7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is Oncolys BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oncolys BioPharma undervalued compared to its fair value and its price relative to the market?

7.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2OB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2OB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2OB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2OB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2OB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2OB is overvalued based on its PB Ratio (7.7x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Oncolys BioPharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

95.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2OB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 2OB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2OB's is expected to become profitable in the next 3 years.

Revenue vs Market: 2OB's revenue (52.8% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 2OB's revenue (52.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2OB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oncolys BioPharma performed over the past 5 years?

24.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2OB has high quality earnings.

Growing Profit Margin: 2OB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if 2OB's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare 2OB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2OB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 2OB has a negative Return on Equity (-25.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Oncolys BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: 2OB's short term assets (¥3.4B) exceeds its short term liabilities (¥240.8M)

Long Term Liabilities: 2OB's short term assets (¥3.4B) exceeds its long term liabilities (405.2M)


Debt to Equity History and Analysis

Debt Level: 2OB's debt to equity ratio (14.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 2OB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 2OB has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2OB's debt is covered by short term assets (assets are 6.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2OB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2OB has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 18.6% each year


Next Steps

Dividend

What is Oncolys BioPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2OB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2OB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2OB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2OB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2OB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Oncolys BioPharma's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average board tenure


CEO

Yasuo Urata (64yo)

15.7yrs

Tenure

0

Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT P ...


Board Age and Tenure

6.7yrs

Average Tenure

64yo

Average Age

Experienced Board: 2OB's board of directors are considered experienced (6.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.9%.


Management Team

  • Yasuo Urata (64yo)

    CEO, President & Representative Director

    • Tenure: 15.7yrs
  • Yasunari Kashihara (54yo)

    VP of Business Development & Director

    • Tenure: 11.7yrs
  • Keiji Yoshimura (64yo)

    Vice President & Director

    • Tenure: 6.7yrs

Board Members

  • Shiro Ohki (76yo)

    External Auditor

    • Tenure: 8.2yrs
  • Yasuo Urata (64yo)

    CEO, President & Representative Director

    • Tenure: 15.7yrs
  • Fumio Urano (76yo)

    External Director

    • Tenure: 6.7yrs
  • Yasunari Kashihara (54yo)

    VP of Business Development & Director

    • Tenure: 11.7yrs
  • Michihiro Yamaoka (53yo)

    Outside Auditor

    • Tenure: 2.7yrs
  • Keiji Yoshimura (64yo)

    Vice President & Director

    • Tenure: 6.7yrs
  • Katsufusa Tachiya

    Corporate Auditor

    • Tenure: 2.7yrs

Company Information

Oncolys BioPharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncolys BioPharma Inc.
  • Ticker: 2OB
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥28.057b
  • Listing Market Cap: JP¥234.171m
  • Shares outstanding: 14.21m
  • Website: https://www.oncolys.com

Number of Employees


Location

  • Oncolys BioPharma Inc.
  • Toranomon Towers Office
  • 4-1-28 Toranomon
  • Tokyo
  • 105-0001
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4588TSE (The Tokyo Stock Exchange)YesCommon SharesJPJPYDec 2013
2OBDB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2013

Biography

Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumour diagnostic agents. The company’s product pipeline includes ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 21:55
End of Day Share Price2019/11/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.